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GENDER IDENTITY DISORDER (GID) is a con-
dition in which an individual suffers from a significant 
gender divergence between his or her actual biological 
sex and the gender to which he or she identifies.  The 
concept of GID was introduced in the 20th century [1], 
and the number of patients diagnosed with this condi-
tion has been increasing in the past decade.  Patients 
are treated with the cross-sex hormone in order to 
reduce the characteristics of their biological sex and 
develop the features of the opposite sex to which they 
feel they belong.  Therefore, testosterone replacement 
therapy (TRT) is often administered in female to male 
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Abstract.  Gender identity disorder (GID) results from a disagreement between a person’s biological sex and the gender to 
which he or she identifies.  With respect to the treatment of female to male GID, testosterone replacement therapy (TRT) is 
available.  The uric acid (UA) level can be influenced by testosterone; however, the early effects and dose-dependency of 
TRT on the serum UA concentration have not been evaluated in this population.  We herein conducted a dose-response 
analysis of TRT in 160 patients with female to male GID.  The TRT consisted of three treatment groups who received 
intramuscular injections of testosterone enanthate: 125 mg every two weeks, 250 mg every three weeks and 250 mg every 
two weeks.  Consequently, serum UA elevation was observed after three months of TRT and there was a tendency toward 
testosterone dose-dependency.  The onset of hyperuricemia was more prevalent in the group who received the higher dose.  
We also demonstrated a positive correlation between increased levels of serum UA and serum creatinine.  Since the level 
of serum creatinine represents an individual’s muscle volume and the muscle is a major source of purine, which induces 
UA upregulation, the serum UA elevation observed during TRT is at least partially attributed to an increase in muscle mass.  
This is the first study showing an association between serum UA elevation and a TRT-induced increase in muscle mass.  
The current study provides important information regarding TRT for the follow-up and management of the serum UA 
levels in GID patients.
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GID patients to promote male sex characteristics, such 
as a beard, body hair, increased muscle mass and a 
deeper voice [2-6].  However, testosterone adminis-
tration also leads to side effects, including water and 
sodium retention, hypertension, increased erythropoi-
esis, an increased low-density lipoprotein (LDL) level, 
a decreased high-density lipoprotein (HDL) level, ele-
vation of liver enzymes, induction of obesity and acne 
and emotional and psychiatric problems [2-6]. 
Uric acid (UA) is the end product of purine metab-
olism in humans.  It is endogenously produced as a 
metabolite in the liver and primarily excreted by the 
kidneys and intestines [7].  Physiologically, the serum 
UA concentration increases with age and is higher in 
males than age-matched females [8].  The UA val-
ues are lower in females of childbearing age and, in 
postmenopausal females, increase to levels similar to 
those observed in males [7, 8].  On the other hand, 
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Kg, and no significant differences were observed in 
body weight between the three TRT dosage groups.
Testosterone replacement therapy and follow-up
TRT was administered via regular intramuscular 
injections of testosterone enanthate in the outpatient 
clinic.  The patients were divided into three groups 
based on the dose: 125 mg every two weeks, 250 mg 
every three weeks and 250 mg every two weeks.  The 
patients selected their preferred dosage based on the 
visit interval and cost of treatment.  The examination 
conducted at the initial visit included measurement of 
the serum UA concentration and serum creatinine con-
centration and hormonal tests of testosterone and estra-
diol.  The remaining evaluations consisted of an inter-
view, physical examination, chromosomal study, blood 
tests (CBC: complete blood cell count), biochemical 
tests (ALT: alanine aminotransferase, AST: aspartate 
aminotransferase), coagulation parameter measure-
ments (PT: prothrombin time, aPTT: activated partial 
thromboplastin time), urinalysis and electrocardio-
gram.  At three, six and 12 months after the initiation 
of TRT, all tests were repeated, except for the chro-
mosomal study and electrocardiogram.  Patients who 
discontinued the TRT, required changes in the dosage 
or received sex reassignment surgery during the fol-
low-up period were excluded from this study.  A retro-
spective study was carried out with respect to the tes-
tosterone dosage and serum UA concentrations.
Blood sample measurements
The serum samples were obtained in the afternoon 
at Okayama University Hospital and stored at −70°C 
until the analyses performed at the laboratory of SRL 
Inc. (Tokyo, Japan).  The assays of serum testosterone 
and estradiol were performed using an electrochemi-
luminescence immunoassay (ECLIA), as previously 
described [6].  The serum testosterone level was mea-
sured as the total testosterone level; the standard value 
ranged from 131~871 ng/dL in males and 11~47 ng/
dL in females.  The standard value of the serum estra-
diol level ranged from 15~35 pg/mL in males and 
20~550 pg/mL in nonpregnant females before meno-
pause.  Since many patients came to our clinic at their 
convenient timing of the blood sampling during TRT, 
we could not determine the exact timing of hormonal 
tests in relation to the latest testosterone injection. 
The serum UA level was measured using the enzy-
matic method, in which UA was oxidized by uricase. 
it is recommended to treat hyperuricemia (≥7.0 mg/
dL) with dietary therapy and/or pharmacotherapy [9] 
because a higher level of serum UA is associated with 
an increased risk of disease, including gouty arthritis, 
cardiovascular disease, renal dysfunction, urinary tract 
stones, hypertension and diabetes mellitus [7, 8]. 
Recently, TRT has become more diverse, including a 
variety of formulations, doses and dose intervals.  The 
most frequently used regimens include 100~250 mg of 
testosterone enanthate administered via intramuscular 
injection every two to three weeks [3, 4].  We previ-
ously reported the physical therapeutic effects of three 
TRT doses (125 mg every two weeks, 250 mg every 
three weeks and 250 mg every two weeks) [6].  We 
experienced that, when TRT is initiated, testosterone 
immediately affects the systemic metabolism in female 
to male GID patients.  Although UA is a possible fac-
tor that can be influenced by testosterone administra-
tion [10-13], the early effects and dose-dependency of 
TRT on the serum UA concentration have not been pre-
viously determined.  As for the effects of testosterone 
on the serum UA level, we herein report our experi-
ence using three TRT doses in the treatment of female 
to male GID. 
Patients & Methods
GID clinic and patients
The GID clinic at Okayama University Hospital 
consists of four clinical departments: psychiatry, urol-
ogy, gynecology and plastic and reconstructive surgery 
[14, 15].  Patients with female to male GID undergo a 
standard psychiatric evaluation to rule out major func-
tional psychiatric disorders, such as schizophrenia, 
mood disorders and neurosis.  The GID clinic provides 
genetic testing, diagnosis, counseling, hormonal ther-
apy and plastic surgery, and all aspects of this study 
were approved by the Ethics Committee of Okayama 
University Hospital [6, 14, 15].  Between January 2002 
and May 2011, a total of 160 Japanese patients were 
diagnosed with female to male GID and treated with 
testosterone replacement therapy (TRT) in the GID 
clinic.  There were 107 patients in the low-dose group 
(125 mg every two weeks), 21 patients in the middle-
dose group (250 mg every three weeks) and 32 patients 
in the high-dose group (250 mg every two weeks).  The 
average patient ages in the three TRT dose groups were 
24.9 ± 0.5, 26.1 ± 1.2 and 28.1 ± 1.0 years, respectively. 
The average body weight of all patients was 57.0 ± 1.0 
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Hyperuricemia was defined as a UA level of ≥7.0 mg/
dL, which is commonly used to define a high serum UA 
concentration in the general population [9].  The level 
of serum creatinine was typically determined accord-
ing to the enzymatic method. 
Statistical analysis
The data are expressed as the mean ± standard error 
(S.E.), if not otherwise specified.  Paired Student’s 
t-test was performed for the statistical analysis between 
the pretreatment and posttreatment values.  An anal-
ysis of variance (ANOVA) and Bonferroni/Dunn test 
was used for the statistical analysis between the dos-
age groups.  We conducted a linear regression analysis 
to determine the correlation between the rate of serum 
creatinine increase and the rate of serum UA increase 
after three months of TRT.  Differences were consid-
ered to be statistically significant at p <0.05.
Results
Changes in the serum UA levels after TRT
We first analyzed the serum uric acid (UA) concentra-
tions of all patients before and during TRT.  The levels 
were compared between the pretreatment values and the 
values obtained at three, six and 12 months after the ini-
tiation of TRT.  Statistically significant elevation of the 
serum UA concentration was observed after three months 
of TRT, and this elevated level was maintained until at 
least one year of TRT (Fig. 1).  We also conducted a dose-
response analysis of TRT in terms of the effects on the 
serum uric acid concentration.  We compared the three 
dosage groups (intramuscular injection of testosterone 
enanthate; 125 mg every two weeks, 250 mg every three 
weeks and 250 mg every two weeks).  After three months 
of TRT, a significantly higher rate of serum UA increase 
was observed in the 250 mg every two weeks group in 
comparison to that observed in the other two groups (Fig. 
2).  We thus found that there was a tendency toward tes-
tosterone dose-dependency in serum UA elevation. 
We next evaluated the onset of hyperuricemia 
induced by TRT, in which hyperuricemia was defined as 
a serum UA concentration of ≥7.0 mg/dL.  No patients 
had hyperuricemia before TRT; however, patients 
with hyperuricemia were observed in all three dosage 
groups, even at three months after the initiation of TRT 
(Fig. 3).  Patients with hyperuricemia were more prev-
alent in the high-dose group, thus indicating testoster-
one dose-dependency at the onset of hyperuricemia. 
Fig. 1  The serum uric acid (UA) concentrations of all patients 
before and during TRT are shown. The levels are compared 
between the pretreatment values and the values obtained 
at three, six and 12 months after the initiation of TRT. A 
significant difference (*p<0.05) was observed between 
the pretreatment levels and the levels at three, six and 12 
months after TRT initiation.
Fig. 3  The percentages of patients with onset of hyperuricemia at 
three months after the initiation of TRT in the three dosage 
groups are shown. Hyperuricemia was defined as a serum 
UA concentration of ≥7.0 mg/dL.
Fig. 2  The rates of serum UA increase after three months of TRT in 
the three dosage groups are shown. A significant difference 
(*p<0.05) was observed between the group treated with 
250 mg every two weeks and the other dosage groups.
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Hormonal parameters
The serum testosterone level at three, six and 12 
months after the initiation of TRT was averaged and 
used in each patient.  Since the hormonal examina-
tions of each patient were conducted on different days 
after the latest testosterone injection, the serum testos-
terone values represent the average level of testoster-
one observed during TRT.  The average testosterone 
level significantly increased compared to the pretreat-
ment level following TRT in all three dosage groups 
(Fig. 4A).  The testosterone level reached 700~800 ng/
dL in each treatment group, and there were no signifi-
cant differences in the testosterone levels between the 
groups.  On the other hand, the serum estradiol levels 
significantly decreased during TRT in comparison to 
the pretreatment levels.  Similar to the levels of tes-
tosterone, the values of estradiol indicated the average 
serum estradiol level during TRT in each dosage group. 
There were also no significant differences between the 
three dosage groups in terms of the average estradiol 
level (Fig. 4B).
Correlation between increases in serum creatinine 
and serum UA
In order to analyze the correlation between the 
increase in serum creatinine and the increase in serum 
UA, we conducted a linear regression analysis among 
the entire population of patients.  We evaluated the rate 
of serum creatinine increase (%) and the rate of serum 
UA increase (%) after three months of TRT.  A scat-
tergram and linear regression analysis showed a sta-
tistically significant positive correlation between the 
increase in serum creatinine and the increase in UA 
(regression-coefficient, 0.59; 95% CI, 0.296-0.883; p 
= 0.0001) (Fig. 5).  Since the level of serum creatinine 
represents individual muscle volume and has been dem-
onstrated to be a reliable biomarker of skeletal muscle 
mass [16], the results indicate a correlation between an 
increase in muscle mass and serum UA elevation at the 
examined time points of TRT. 
Side effects of TRT
No significant adverse events were observed in any 
of the dosage groups during this study.  All patients 
were satisfied with the therapeutic effects of TRT, and 
no discontent was observed during treatment.  TRT did 
not induce adverse symptoms or diseases due to hyper-
uricemia in any of the dosage groups.  There was a ten-
dency toward increased values of systolic and diastolic 
Fig. 4  The serum concentrations of testosterone (A) and estradiol 
(B) before and during TRT are shown. The average levels 
of testosterone and estradiol during TRT were calculated 
in each patient. The bar graph indicates the average 
concentrations of testosterone and estradiol during TRT in 
each dosage group. [n.s.] indicates no significant differences 
between the three dosage groups.
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ment therapy reduces the serum UA concentration and 
increases urinary UA excretion [10].  Estrogen replace-
ment therapy also reduces the serum UA concentra-
tions in hyperuricemic postmenopausal females [11]. 
With respect to TRT, only two reports have shown that 
testosterone treatment for female to male gender reas-
signment leads to increased serum UA concentrations 
and reduced renal excretion of UA [12, 13].  Our cur-
rent study also demonstrated serum UA upregulation 
induced by testosterone administration.  This is the first 
study to show TRT dose-dependent effects in this pop-
ulation.  These results suggest that an increased serum 
testosterone level and/or a decreased serum estradiol 
level induced by TRT results in serum UA elevation. 
As for the mechanisms underlying the TRT-induced 
increases in the serum UA concentration, it seems 
likely that sex hormones primarily influence the serum 
UA concentration via changes in renal UA excretion 
[10-13].  Testosterone and estradiol exhibit suppressing 
and enhancing effects, respectively, on renal UA excre-
tion, and this theory also explains age and sex differ-
ences in the serum UA levels. 
To further clarify the mechanisms by which TRT ele-
vates the serum UA concentrations in female to male 
GID patients, we examined the association between 
increases in serum UA and other blood or physical 
examination parameters.  As for the changes of serum 
testosterone level and body mass index, there was no 
significant association with the increases in serum UA 
level (data not shown).  Notably, we demonstrated a 
positive correlation between increased levels of serum 
UA and serum creatinine after three months of TRT, 
indicating that the serum UA elevation observed in the 
patients was at least partially attributed to an increase 
in muscle mass during the early phase of TRT.  We thus 
found a novel association between serum UA elevation 
and an increase in muscle mass in patients with TRT. 
As for the manner in which an increase in muscle mass 
upregulates the serum UA concentration, various the-
blood pressure during the observation period; however, 
no definitive cardiovascular diseases were clinically 
relevant.  There was a trend toward increased levels 
of red blood cell (RBC), hemoglobin and hematocrit 
on the CBC examinations conducted during TRT.  No 
clinically significant changes were observed in the lev-
els of liver enzymes or coagulation parameters during 
the treatment period (Table 1).
Discussion
Regarding the serum UA concentration after TRT, 
to our knowledge, this is the first study to conduct an 
early phase and dose-dependent analysis of female to 
male GID patients.  The serum UA levels were found 
to be upregulated after three months of TRT, and the 
elevated levels were maintained until at least one year 
of TRT.  We showed that there was a tendency toward 
testosterone dose-dependency in serum UA elevation. 
We also demonstrated that the onset of hyperuricemia 
was more prevalent in the high-dose group.  As shown 
in previous studies, maximal serum testosterone lev-
els are achieved immediately after testosterone injec-
tion, and early testosterone levels are TRT dose-depen-
dent [6, 17].  Therefore, the higher serum testosterone 
concentration induced by a higher dose of TRT causes 
dose-dependent serum UA upregulation.  On the other 
hand, as for the average values of serum testosterone 
and estradiol in the three TRT dosage groups, there 
was no dose-dependent elevation or suppression in any 
group.  The absence of dose-dependency in these hor-
mone levels is consistent with the findings of a previ-
ous study, and the serum hormone values measured at 
variable times of sampling in relation to the last testos-
terone injection did not reflect the TRT dose [6].
Several authors have previously examined the influ-
ence of testosterone and estradiol on the serum UA level 
[10-13].  A study of patients undergoing male to female 
gender reassignment reported that estrogen replace-
Table 1  The laboratory data of pretreatment and after three months of TRT.
Parameter Pre-treatment After 3 months of TRT p value
RBC (× 106/mm3) 4.36 ± 0.03 4.89 ± 0.03 < 0.0001 
Hemoglobin (g/dL) 13.3 ± 0.08 14.2 ± 0.12 < 0.0001 
Hematocrit (%) 39.5 ± 0.23 42.8 ± 0.33 < 0.0001 
ALT (IU/L) 16.6 ± 1.33 16.6 ± 0.72 0.93
AST (IU/L) 18.6 ± 0.85 20.5 ± 0.81 0.11
PT (seconds) 12.5 ± 0.68 11.6 ± 0.11 0.13
aPTT (seconds) 33.2 ± 0.32 32.8 ± 0.49 0.16
1326 Kurahashi et al.
also indicates an association between the UA level 
and cardiovascular morbidity and suggests that mor-
tality is greater in females than in males in middle life 
[23].  Although no adverse symptoms or diseases due 
to hyperuricemia were observed in any of the dosage 
groups during this study, TRT substantially elevates the 
serum UA levels in female to male GID patients.  We 
demonstrated that the early onset of hyperuricemia is 
induced by TRT, even though the treatment period was 
short at three months and the patients were young and 
intrinsically female.  If older patients are treated with 
long-term TRT, the progression of serum UA eleva-
tion and other metabolic effects may increase the risk 
of diseases, such as gout and cardiovascular disease 
[7-9, 23].  Moreover, it is possible that TRT acceler-
ates the onset of hyperuricemia and gout in combina-
tion with underlying genetic risks of these conditions. 
Therefore, serum UA elevation is an important side 
effect to be addressed, and the medical team should be 
alert to the possibility of excess hyperuricemia from 
the early phase of TRT.  The information provided here 
is available for both patients and medical doctors to 
determine the optimal initial dose of TRT and to fol-
low-up and manage the serum UA level. 
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ories are conceivable in terms of muscle metabolism. 
The anabolic effects of testosterone administration on 
muscle mass have been clearly demonstrated in female 
to male GID patients as well as the general male popu-
lation [2-5].  In addition, muscle mass is considered to 
be a major source of purine, which induces serum UA 
upregulation [18-20].  During rapid increases in mus-
cle mass, TRT induces the active replacement of old 
muscle with newly regenerated muscle.  This process 
is likely to require compensatory muscle cell deple-
tion and can increase the provision of nucleic acids 
and purine to the liver, resulting in increased produc-
tion of UA.  Hence, the rapid increase in muscle mass 
is accompanied by serum UA upregulation due to acti-
vated purine metabolism in these patients.  In addi-
tion, it is possible that increased muscle mass leads to 
greater adenosine triphosphate (ATP) consumption in 
order to obtain more energy.  Increased ATP metabo-
lism causes the release of purine intermediates in the 
muscle and induces serum UA elevation.  Based on our 
experience, once TRT is initiated, some patients with 
female to male GID dramatically achieve a muscu-
lar body through heavy exercise and muscular labor. 
Therefore, we cannot rule out the possibility that heavy 
exercise results in the accumulation of injured muscle 
cells, increasing the metabolism of nucleic acids and 
purine, which then elevates the serum UA concentra-
tion [21, 22]. 
The onset of gout induced by TRT is rare; how-
ever, a case report of the development of gout follow-
ing therapy for female to male gender reassignment 
has previously been reported [13].  Previous research 
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